Entries by admin

TMEM16A Channel Function Does Not Influence Goblet Cell Numbers or Mucin Secretion In The Human Airway Epithelium – NACFC – Nashville – October 2019

TMEM16A Channel Function Does Not Influence Goblet Cell Numbers or Mucin Secretion In The Human Airway Epithelium – NACFC – Nashville – October 2019 Henry Danahay1,2, Alexis Flen, Camille Ehre3, Martin Gosling1,2 1University of Sussex, Brighton, UK; 2Enterprise Therapeutics, UK; 3University of North Carolina, Chapel Hill, USA. A role for the calcium activated chloride channel, […]

EACT Increases Intracellular Calcium Levels by a Tmem16a-Independent Mechanism – NACFC – Nashville – October 2019

EACT Increases Intracellular Calcium Levels by a Tmem16a-Independent Mechanism – NACFC – Nashville – October 2019 Sarah Lilley1, Henry Danahay1,2, Holly Charlton1, Kathryn Adley1, Roy Fox1, Martin Gosling1,2 1University of Sussex, Brighton, UK; 2Enterprise Therapeutics, UK The N-aroylaminothiazole EACT was first described by Namkung et al. (2011) as an activator of the calcium-activated chloride channel, […]

The In Vitro & In Vivo Pharmacology of Novel Tmem16a Potentiator Compounds – NACFC – Nashville – October 2019

The In Vitro & In Vivo Pharmacology of Novel Tmem16a Potentiator Compounds – NACFC – Nashville – October 2019 Henry Danahay1,2, Sarah Lilley1, Holly Charlton1, Roy Fox1, Brian Button3, Juan Sabater4, Martin Gosling1,2 1University of Sussex, Brighton, UK; 2Enterprise Therapeutics, UK; 3University of North Carolina, Chapel Hill, USA; Mount Sinai Medical Center, Miami, USA TMEM16A […]

Enterprise Therapeutics awarded up to £5.7M ($7M) from Cystic Fibrosis Foundation to Support Clinical Development of Novel Chloride Channel Modulator

Support for clinical development up to end of Phase 2 for ETD002, first-in-class TMEM16A potentiator for the treatment of cystic fibrosis Milestone Funding through Cystic Fibrosis Foundation’s Therapeutics Development Award programme Brighton, UK, 15 October 2019: Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the […]

ECFS Clinical Meeting Liverpool TMEM16A potentiator

ECFS Clinical Meeting Liverpool TMEM16A potentiator Objectives: TMEM16A (ANO1) is a Ca2+-activated, alternative chloride channel expressed in the human airway epithelium. A potentiator of TMEM16A is predicted to enhance the secretion of chloride and thereby increase mucus hydration and clearance in the CF lung. Our aim is to discover and test the efficacy of novel […]

A systematic comparison of the profiles of inhaled ENaC blocker candidates on mucociliary clearance: are we under-dosing in clinical studies?

A systematic comparison of the profiles of inhaled ENaC blocker candidates on mucociliary clearance: are we under-dosing in clinical studies? Henry Danahay1, Clive McCarthy1 and Martin Gosling1 1Enterprise Therapeutics, UK Objectives: Recent clinical studies with ENaC modulator compounds have challenged the validity of the target for treating CF lung disease. Our aim was to establish […]

The pharmacology of novel TMEM16A potentiator compounds

The pharmacology of novel TMEM16A potentiator compounds Henry Danahay1,2, Sarah Lilley1, Holly Charlton1, Roy Fox1, Brian Button3, Martin Gosling1,2 1University of Sussex, Brighton, UK; 2Enterprise Therapeutics, UK; 3University of North Carolina, Chapel Hill, USA TMEM16A was recently identified as a calcium-activated chloride conductance and a key orchestrator of anion secretion in the human airway epithelium […]

TMEM16A channel function does not influence goblet cell numbers in the human airway epithelium

TMEM16A channel function does not influence goblet cell numbers in the human airway epithelium Henry Danahay1,2, Martin Gosling1,2 1University of Sussex, Brighton, UK; 2Enterprise Therapeutics, UK. A role for the calcium activated chloride channel, TMEM16A, in the regulation of airway goblet cell populations has been recently reported (Kondo et al., 2017; Lin et al., 2015; […]

EACT increases intracellular calcium levels by a TMEM16A-independent mechanism

EACT increases intracellular calcium levels by a TMEM16A-independent mechanism Sarah Lilley1, Henry Danahay1,2, Holly Charlton1, Kathryn Adley1, Roy Fox1, Martin Gosling1,2 1University of Sussex, Brighton, UK; 2Enterprise Therapeutics, UK The N-aroylaminothiazole EACT was first described by Namkung et al. (2011) as an activator of the calcium-activated chloride channel, TMEM16A. Subsequently, EACT has been used as […]